麻豆视频

skip to main content

ProfessionalsChristopher M. Wilson

Christopher M. Wilson
Partner

Tel: +1-202-223-7301
Fax: +1-202-330-5711
cmwilson@paulweiss.com

+1-202-223-7301
Washington

2001 K Street, NW
Washington, DC 20006-1047
Fax: +1-202-330-5711

+ vCard ADD TO CONTACTS
Education 
Bar Admissions 
Education 
Bar Admissions 

Chris Wilson is a litigation partner in the Antitrust Group. Chris advises clients on a full range of antitrust matters, including merger control, cross-border antitrust investigations and private party litigation involving complex antitrust and consumer protection issues, including matters implicating the Hart-Scott-Rodino (HSR) merger review process, the Sherman Act, the Clayton Act, the FTC Act, and international and state competition statutes.

EXPERIENCE

Chris鈥檚 areas of expertise include merger enforcement, interlocking directorates, joint ventures, compliance programs, and employee 鈥渘o-poach鈥 agreements. He has advised on cross-border investigations involving the European Union, the United Kingdom, Canada, Brazil, Japan, Korea and Saudi Arabia, among other jurisdictions, and has handled merger reviews and other antitrust matters involving multiple industries, including health insurance, transportation, telecommunications, technology, energy, agriculture and biotechnology.

Prior to his private practice, Chris was a trial attorney in the Transportation, Energy & Agriculture Section of the U.S. Department of Justice鈥檚 Antitrust Division. During his time in the Division, he managed or played a key role in numerous high-profile matters, including merger reviews for Halliburton-Baker Hughes, Aetna-Humana, Anthem-Cigna, Alaska Airlines-Virgin and CVS-Aetna. Chris received the Antitrust Division鈥檚 Award of Distinction on two separate occasions.

Chris鈥檚 notable representations include:

  • Endeavor Energy Resources in its $26 billion merger with Diamondback Energy;
  • Envestnet in its $4.5 billion take-private deal with Bain Capital;
  • Pioneer Natural Resources in its $65 billion merger with ExxonMobil;
  • Platinum Equity in its $5.25 billion acquisition of Solenis;
  • GE Healthcare in its $1.45 billion acquisition of BK Medical;
  • Xylem in its $7.5 billion acquisition of Evoqua;
  • Spark Therapeutics in its $4.3 billion sale to Roche; and
  • Stone Canyon Industries in its $3 billion acquisition of Morton Salt

鈥婭NDUSTRY AWARDS & RECOGNITIONS

Among other recognitions, Chris was recently included in the Lawdragon 500 Leading Global Antitrust & Competition Lawyers list. During his time at the Department of Justice, Chris was twice awarded the Antitrust Division鈥檚 Award of Distinction.

PROFESSIONAL AFFILIATIONS AND THOUGHT LEADERSHIP

Chris frequently writes and speaks on antitrust topics for numerous publications and podcasts, including Concurrences, Law360, the Curious Amalgam, and The Deal, among others. Chris has also been published in numerous antitrust newsletters and publications.

While at Columbia Law School, Chris was a Harlan Fiske Stone scholar and served as an editor on the聽Columbia Business Law Review.

© 2025 Paul, Weiss, Rifkind, Wharton & Garrison LLP

Privacy Policy